Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines

Int J Oncol. 2000 Mar;16(3):537-41. doi: 10.3892/ijo.16.3.537.


To determine whether alterations of the CDKN2/p16 might be involved in HPV-positive cervical cancers, we examined for alterations of this gene and function of the protein p16 to interact with CDK4 in 5 cervical cancer cell lines. No alteration of this gene was detected. Proteins for p16 and CDK4 were normally expressed and function of p16 to interact with CDK4 was not abrogated in these cell lines. These cell lines were human papillomavirus (HPV)-positive and carried wild-type p53. These findings suggest that phosphorylation of pRb by CDK4 is not critical in the carcinogenesis or in the establishment of HPV-positive cervical cancer cell lines, since HPV E6 or E7 viral-transforming proteins inactivate p53 and pRb tumor suppressor protein function, resulting in deregulated progression of the cell cycle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase Inhibitor p16 / analysis
  • Cyclin-Dependent Kinases / analysis
  • Female
  • Genes, p16*
  • Humans
  • Papillomaviridae / isolation & purification*
  • Proto-Oncogene Proteins*
  • Retinoblastoma Protein / analysis
  • Tumor Cells, Cultured
  • Uterine Cervical Neoplasms / genetics*
  • Uterine Cervical Neoplasms / virology


  • Cyclin-Dependent Kinase Inhibitor p16
  • Proto-Oncogene Proteins
  • Retinoblastoma Protein
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinases